Area of research
Genetics · Biotechnology
Research interest
Research interests include Medicine, Internal medicine, Temozolomide, Oncology, Clinical endpoint, and Glioblastoma.
A Digital Asthma Self-Management Program for Adults
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma
Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial
BRAF–MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma
Non-viral precision T cell receptor replacement for personalized cell therapy
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment
Alliance A071601: Phase II trial of BRAF/MEK inhibition in newly diagnosed papillary craniopharyngiomas.
Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma
Somatostatin Receptor–Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma: Individual Patient Data Meta-analysis
Development and external validation of a prognostic tool for COVID-19 critical disease
Optimizing Neuro-Oncology Imaging: A Review of Deep Learning Approaches for Glioma Imaging
European mtDNA Variants Are Associated With Differential Responses to Cisplatin, an Anticancer Drug: Implications for Drug Resistance and Side Effects
LTBK-08. TOCA 511 & TOCA FC VERSUS STANDARD OF CARE IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
Deep-Learning Convolutional Neural Networks Accurately Classify Genetic Mutations in Gliomas
Management of low-grade glioma: a systematic review and meta-analysis
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
Imaging Genetic Heterogeneity in Glioblastoma and Other Glial Tumors: Review of Current Methods and Future Directions
ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma.
IMCT-08ReACT: LONG-TERM SURVIVAL FROM A RANDOMIZED PHASE II STUDY OF RINDOPEPIMUT (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA
Corrigendum to “Clinical Practice Experience With Novo TTF-100A™ System for Glioblastoma: The Patient Registry Dataset (PRiDe)”
Clinical Practice Experience With NovoTTF-100A™ System for Glioblastoma: The Patient Registry Dataset (PRiDe)
Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors
EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY